Shots:
- Avenzo Therapeutics and DualityBio have signed an exclusive license agreement to develop, manufacture & commercialize the former’s AVZO-1418/DB-1418 across the globe (excl. Greater China)
- As per the terms, DualityBio will get $50M upfront, ~$1.15B development, regulatory and commercial milestones as well as tiered royalties in Avenzo’s territory
- AVZO-1418, an EGFR/HER3-targeting ADC developed using DualityBio’s DIBAC platform, showed strong tumor binding affinity & efficacy against in EGFR-resistant/low & HER3-resistant solid tumors. IND-enabling studies are underway, with FIH trial planned in 2025
Ref: Avenzo Therapeutics | Image: BioNTech & Avenzo Therapeutics
Related News:- Moderna’s Patent Revoked by the European Patent Office (EPO) due to BioNTech Vaccine Dispute
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
